-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Biogen, Raises Price Target to $246

Benzinga·02/09/2026 14:48:40
Listen to the news
Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $185 to $246.